Table 4 Polymorphisms and toxicity due to treatment of colorectal cancer patients

ERCC1-rs11615

Stomatitis^a

 T/T

14/70 (20.0)

 C/T + C/C

8/94 (8.5)

ERCC1-rs11615

Nausea

 T/T

24/37 (64.9)

 C/T + C/C

48/58 (82.8)

ERCC2-rs13181

Eye reactions

 A/A

7/37 (18.9)

 A/C + C/C

27/58 (46.6)

ERCC2-rs13181

Thrombocytopenia

 A/A

8/36 (22.2)

 A/C + C/C

31/59 (52.5)

ERCC2-rs238406

Thrombocytopenia

 C/C

16/28 (57.1)

 C/A + A/A

23/67 (34.3)

ERCC2-rs13181

Dose reduction/discontinuation^a

 A/A

38/70 (54.3)

 A/C + C/C

69/96 (71.9)